Deutsche Bank Ups Illumina Stock to Buy | GenomeWeb
NEW YORK (GenomeWeb News) — Investment bank Deutsche Bank today upgraded Illumina’s stock to ‘buy’ from ‘hold’ after the company last week reported strong fourth-0quarter revenues but warned of high costs this year.
 
As GenomeWeb News reported last week, Illumina said total revenues for the three months ended Dec. 31, 2006, jumped 163 percent as R&D spending rose 17 percent and profit soared.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.